Martin Shkreli Was Apparently Live Streaming When FBI Agents Called

Shkreli, Greebel plead 'not guilty' in securities fraud case - Bloomberg

Martin Shkreli and Evan Greebel plead 'not guilty' in securities fraud case, according to Bloomberg. Greebel was charged alongside Shkreli.

Streetinsider.com's Hot Lunchtime Reads 12/17: (MU) (KBIO) (AMZN)

The following is a list of notable articles to help get you through the lunch hour:SEC Charges Martin Shkreli with Fraud -> Read this!

Morgan Stanley Sees Limited Downside in Micron (MU) and Upgrades Stock to Overweight -> Read this!

Forget FANG, Look at BAGEL in 2016 -> Read this!

Martin Shkreli 'essentially ran his companies like a ponzi scheme' - US Attorney

Martin Shkreli "essentially ran his companies like a ponzi scheme" - US Attorney

SEC Charges Martin Shkreli with Fraud

(Updated - December 17, 2015 12:07 PM EST)

The Securities and Exchange Commission today charged Martin Shkreli, former CEO of pharmaceutical company Retrophin, with committing fraud during a five-year period when he also was working as a hedge fund manager.

The SEC alleges that Martin Shkreli misappropriated money from two hedge funds he founded and made material misrepresentations to investors among other widespread misconduct. The SEC also charged Retrophins former outside counsel and corporate secretary Evan Greebel with aiding and abetting certain aspects of Shkrelis alleged fraud.

In a parallel action, the U.S. Attorneys Office for the... More

More Shkreli Arrest Photos Surface (KBIO)

More images have been released of the arrest of Martin Shkreli.

Shkreli is the CEO of Turing Pharma and... More

Photo of Martin Shkreli Being Arrested by FBI Agents

Reuters photo of KaloBios Pharma (NASDAQ: KBIO) CEO, Martin Shkreli, getting arrested this morning in New York.

Shkreli Indictment Document Posted (KBIO)

Embedded below is the indictment for Matin Shkreli, CEO of KaloBios (Nasdaq: KBIO) and Turing Pharma.

NASDAQ Affirms Trading Halt on KaloBios Pharma (KBIO)

The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted today in KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) at 06:48:07 Eastern Time for "additional information requested" from the company at a last price of $23.59.

Trading will remain halted until KaloBios... More